ストックスクリーナーアプリを入手
3.21
10.34%
-0.37
アフターアワーズ：
3.30
0.09
+2.80%
Mainz Biomed N V (MYNZ) 最新ニュース
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia
Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks
Mainz Biomed secures license for pancreatic cancer test - Investing.com India
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times
Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq
Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
(MYNZ) Trading Advice - Stock Traders Daily
Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire
Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq
First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
How To Trade (MYNZ) - Stock Traders Daily
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire
Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq
Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan
A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News
The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed Regains Compliance With Nasdaq Listing Rules - Nasdaq
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial - Nasdaq
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire
Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan
1.12%
1.76%
大文字化:
|
ボリューム (24 時間):